Allergy News and Research RSS Feed - Allergy News and Research

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.
Family Doctor Medical Clinic opens new paediatric treatment centre in Moscow

Family Doctor Medical Clinic opens new paediatric treatment centre in Moscow

Family Doctor Medical Clinic ltd announces opening of new paediatric treatment facility in Moscow. [More]
Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents. [More]
Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines

Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen. [More]
Researchers probe possibility of reversing medications' adverse cognitive effects

Researchers probe possibility of reversing medications' adverse cognitive effects

Whether the adverse cognitive effects of medications can be reversed is of significant importance to an aging population, their caregivers and their families, as well as to an overburdened health care system. [More]
Bronchial thermoplasty for severe asthma: an interview with Dr. Rob Niven

Bronchial thermoplasty for severe asthma: an interview with Dr. Rob Niven

Internationally, severe asthma is defined as anybody who is on maximum therapy, which has no measurable side effects, but still have symptoms of persistent asthma. In the UK, that effectively means people who require oral steroids for their asthma two or more times a year. [More]
Income, race and ethnic origin may play more potent roles in asthma risk

Income, race and ethnic origin may play more potent roles in asthma risk

Challenging the long-standing belief that city dwellers suffer disproportionately from asthma, the results of a new Johns Hopkins Children's Center study of more than 23,000 U.S. children reveal that income, race and ethnic origin may play far more potent roles in asthma risk than kids' physical surroundings. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Researchers identify novel signaling pathway that triggers allergic asthma response

Researchers identify novel signaling pathway that triggers allergic asthma response

Researchers at the University of California, San Diego School of Medicine, with collaborators in Korea and Scotland, have identified a novel signaling pathway critical to the immune response of cells associated with the initiation of allergic asthma. [More]
Leading microbiologist warns of killer fungi’s increasing threat

Leading microbiologist warns of killer fungi’s increasing threat

A leading microbiologist has warned of the increasing threat that killer fungi poses to humans and the environment. [More]
NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs. [More]
Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

Study assesses therapeutic benefits of new oral immunotherapy for children allergic to wheat

The study carried out by researchers from the Centre for Plant Biotechnology and Genomics along with the Allergy Department of the Hospital Infantil Universitario Niño Jesús of Madrid have shown that, most of the children that received this new oral immunotherapy treatment were able to eat 100 grams of wheat bread without side effects. This result has overcome the risk of accidental ingestion by patients with this allergy. This research could be the basis for large clinical trials with more patients with the aim of assessing the therapeutic benefit of this new approach. [More]
LJI researcher awarded $1.6 million grant to study factors that trigger onset of type 1 diabetes

LJI researcher awarded $1.6 million grant to study factors that trigger onset of type 1 diabetes

The American Diabetes Association has awarded La Jolla Institute researcher Stephanie Stanford, Ph.D., a $1.6 million grant to investigate the genetic and environmental factors that trigger the onset of type 1 diabetes. [More]
H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola. [More]
Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea. [More]
BD Medical announces FDA clearance of BD Intelliport Medication Management System

BD Medical announces FDA clearance of BD Intelliport Medication Management System

BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that the U.S. Food and Drug Administration has cleared the BD Intelliport Medication Management System, the first-of-its-kind medication management solution for manual IV bolus injections. [More]
Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration. [More]
Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

Johnson & Johnson today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. [More]
Researchers use whole genome sequencing to track evolution of chicken flu virus

Researchers use whole genome sequencing to track evolution of chicken flu virus

An international research team has shown how changes in a flu virus that has plagued Chinese poultry farms for decades helped create the novel avian H7N9 influenza A virus that has sickened more than 375 people since 2013. The research appears in the current online early edition of the scientific journal Proceedings of the National Academy of Sciences. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Experimental Ebola vaccine safe and immunogenic in African population

Experimental Ebola vaccine safe and immunogenic in African population

Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus [1] are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year. [More]